Business Context and Reporting Period
This Form 8-K is a current report filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on January 5, 2022. The filing serves as a Regulation FD disclosure regarding the Company's fourth quarter 2021 activity, cash balance, and upcoming events. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol OCUP.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, or debt. The only specific financial metric disclosed in the text is the total common stock outstanding as of December 31, 2021:
- Total Common Stock Outstanding: 18,845,828 shares
Details regarding the cash balance and fourth-quarter activity are referenced as being contained in the attached press release (Exhibit 99.1) but are not explicitly stated in the body of this 8-K filing.
Material Changes
The filing does not detail specific material changes in financial performance compared to prior periods. It notes the issuance of a press release and an updated corporate presentation to the Company's website on January 5, 2022, to communicate fourth-quarter updates.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers. Management notes that forward-looking statements are based on current expectations and are not guarantees of future performance. Actual results may differ materially due to risks and uncertainties. The Company explicitly states that the information in this report and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act.
Investor Verification Checklist
- Verify the specific cash balance and Q4 2021 operational details in the attached Press Release (Exhibit 99.1), as these figures are not in the main text.
- Review the Corporate Presentation (Exhibit 99.2) for updated strategic outlooks and upcoming events.
- Confirm the share count of 18,845,828 against subsequent filings to check for dilution or buybacks.
- Note that the registrant name in the metadata request ("Opus Genetics") differs from the filing ("Ocuphire Pharma"); ensure analysis is applied to the correct entity.